Infantile spasms: Etiology, lead time and treatment response in a resource limited setting

Priyanka Surana a,b, Joseph D. Symonds b,c, Prabhar Srivastava a, Thenral S. Geetha d, Romit Jain a, Ramprasad Vedant d, Sakthivel Murugan d, Subathra Mahalingam d, Vivek Bhargava a, Pradeep Goyal a, Sameer M. Zuberi b,c, Vivek Jain a,*

a Departments of Pediatrics, Pediatric Neurology & Radio Diagnosis, Santokba Durlabhji Memorial Hospital, Jaipur, India
b School of Medicine, University of Glasgow, Glasgow, UK
c Pediatric Neurosciences Research Group, Royal Hospital for Children, Glasgow, UK
d Medgenome Labs, Bangalore, India

ARTICLE INFO
Article history:
Received 10 July 2020
Revised 24 September 2020
Accepted 3 October 2020
Available online 17 October 2020

Keywords:
Infantile spasms
Etiology
Hypoglycemia
Genetic
Lead time

ABSTRACT
This study explores the etiology and lead time to treatment for infantile spasm (IS) patients and their effect on treatment responsiveness, in a limited resource setting. Patients with IS onset age <12 months, seen over 3 years were recruited retrospectively. Clinical information, neuroimaging and genetic results retrieved. Patients categorized into three primary etiological groups: Structural (including Structural Genetic), Genetic, and Unknown. The effect of etiology and lead time from IS onset to initiating appropriate treatment on spasm resolution, evaluated. Total 113 patients were eligible. Mean IS onset age was 6.86(±4.25) months (M: F 3.3:1). Patients were grouped into: Structural 85, Genetic 11 and Unknown 17. Etiology was ascertained in 94/113 (83.1%) with neonatal hypoglycemic brain injury (NHBI) being the most common (40/113, 36%). A genetic etiology identified in 17 (including 6 Structural Genetic, of which five had Tuberous Sclerosis). Structural group was less likely to be treatment resistant (p = 0.013, OR 0.30 [0.12–0.76]). Median treatment lead time – 60 days. Longer lead time to treatment was significantly associated with resistant spasms (χ² for trend = 10.0, p = 0.0015). NHBI was the commonest underlying cause of IS. There was significant time lag to initiating appropriate treatment, affecting treatment responsiveness.

1. Introduction
Infantile spasms (IS) are a seizure type manifesting in first year of life, as a component of an age-dependent epilepsy syndrome [1]. IS has many underlying causes [2–8]. Studies from resource-limited settings have highlighted neonatal asphyxial brain injury as the commonest acquired cause for IS [4–6]. Neonatal hypoglycemic brain injury (NHBI) is also being increasingly recognized as an important acquired cause of IS [9–11].

Genetic defects have been shown to be another major cause of IS [7,8]. However patients with IS of unknown etiology in published Indian studies [4–6] have not been investigated using comprehensive next generation genetic technologies. Hence etiological data after detailed genetic evaluation of IS patients from developing healthcare setups, still remains limited [8,12].

Studies have suggested that shorter lead time to treatment is associated with a better treatment response and subsequent improved developmental outcome [13,14]. Unfortunately, diagnosis and treatment of IS is often delayed in both developed and developing countries, despite a characteristic hypsarrythmic EEG pattern [4,5,15]. Also only few large scale studies have assessed the effect of etiology on treatment outcome, suggesting a better outcome for patients in the unknown group [13,14]. A recent study though concluded that those in Genetic/Unknown group do not necessarily have a favorable outcome [16].

In this study from a pediatric neurology clinic from Jaipur in North India, we have comprehensively investigated the etiologies of IS by accessing patients’ clinical information including perinatal histories, reviewing the available neuroimaging findings, and retrieving genetic testing results. We have also evaluated associations of etiology and lead time to specific treatment with resolution of spasms.
2. Methods

2.1. Patient selection

In this retrospective cohort study, IS patients with an onset age of <12 months with EEG evidence of hypsarrhythmia or its variants [17], seen over a 3-year period between March 2015–March 2018 were eligible.

2.2. Setting

This study was conducted in the pediatric neurology clinic at Santokba Durlabhji hospital, a tertiary care teaching hospital in Jaipur, North India. Our center is a secondary and tertiary care referral centre for city of Jaipur (Rajasthan), in addition to being a tertiary centre for outlying districts of Rajasthan, and adjoining districts of neighbouring states, Haryana and Punjab.

2.3. Assessment of case records

The following variables were summarized from each case record: Birth details (gestation, birth weight, APGAR), adverse perinatal events (delayed cry, neonatal encephalopathy, neonatal seizures, intensive care admission, feeding issues, blood glucose reports & cerebrospinal fluid results), IS onset age and the age of initial presentation to a pediatric neurologist. If any relevant information was unavailable, it was sought from the families via follow-up visits or calls.

2.4. Investigations

2.4.1. Neuroimaging

Brain Magnetic Resonance Imaging (MRI) was retrieved and findings were confirmed independently by two radiologists. All MRI scans at our centre are performed on a 3 Tesla machine with standard imaging protocols. If patient already has a 1.5 Tesla MRI performed according to standard imaging protocols, prior to visiting us, the neuroimaging is not repeated.

2.4.2. Metabolic testing

All our IS patients without an obvious acquired postnatal cause or a cortical malformation, routinely have a metabolic screen performed including serum ammonia, serum lactate and tandem mass spectroscopy (TMS). These results were retrieved.

2.4.3. Genetic testing

For patients in whom an acquired postnatal cause could not be determined from the history and neuroimaging, genetic testing was performed according to the protocol in Fig. 1.

Next Generation Sequencing with copy number variations (CNVs) was done to identify the disease causal variant using the whole exome capture kit (Exome research panel, Integrated DNA Technologies). The variants were analyzed using Varminer (in-house analysis tool) and interpreted based on American College of Medical Genetics 2015 guidelines [18]. All pathogenic and likely pathogenic variants were included in the final analysis.

Patients who remained without an etiological diagnosis after trio whole exome sequencing (WES) then had array comparative genome hybridization (array aCGH) analysis (affymetrix CytoScan™ 750 K). An exception was for patients with dysmorphic features, who had array aCGH as first line genetic test (Fig. 1).

2.5. Etiology definitions:

- Neonatal asphyxiation and brain injury had a history of resuscitation at birth followed by neonatal encephalopathy with APGAR ≤ 5 at 5 min and/or MRI showing features of hypoxic ischemic encephalopathy or its sequelae [19,20].
- Neonatal hypoglycemic brain injury (NHBI) had feeding issues in the postnatal period with lethargy, apnea and/or seizures associated with a documented blood sugar level of <47 mg%/(<2.6 mmol/l), or MRI features to suggest specific NHBI changes such as bilateral occipital/occipito parietal insult [21,22,23].

2.6. Etiological classification:

Depending on case record review, neuroimaging and genetic results, patients were categorized into etiological groups using the International League Against Epilepsy 2017 classification [24]. Etiological groups were: i) Structural, which was further subdivided into structural-acquired, structural-genetic, and structural unknown; ii) genetic; iii) infectious; iv) immunologic; v) metabolic; and vi) unknown. The structural-unknown group included patients with cortical malformation and a normal comprehensive genetic evaluation.

2.7. Infantile spasm treatment protocol:

All IS patients with Tuberous Sclerosis (TS) are given vigabatrin at our center according to the United Kingdom Infantile Spasm Study (UKISS) protocol [25]. Non-TS patients are treated with oral steroids (40 milligram/day). Intramuscular corticosteroid administration for TS cortis not used at our center. If clinical spasms continue after 14 days of treatment, vigabatrin is added, as per our protocol [25]. Follow up EEGs are not routinely performed if there is clinical cessation of IS.

2.8. Treatment initiation and response classification:

Case notes were reviewed for the time gap between onset of spasms and initiation according to above treatment protocol. Lead-time to initial treatment for infantile spasms was accessed from clinic notes. Lead-time refers to the delay between clinical onset of spasms and initiation of treatment [13]. The lead time was categorized into four time periods (<7 days, 8–14 days, 15 days to 2 months, and > 2 months). The effect of lead time on treatment responsiveness was analyzed. The treatment response was noted from follow-up clinic notes. Spasm cessation for at least 3 months without relapse or progression to other seizure types was considered as complete clinical response (responders). This favorable outcome was studied in relation to lead time in starting treatment. The patients were classified as incomplete clinical responders (non-responders) if they continued to have IS despite use of steroids and vigabatrin up to a 3-month follow-up appointment, or had progressed to other seizure types or had relapsed within this period. Only patients with at least three months’ follow up after initiation of treatment according to UKISS protocol 2, were included in the final analysis for treatment response.

2.9. Neuro developmental follow up:

All patients with IS are routinely reviewed for their neurodevelopmental progress and co-morbidities by the attending pediatric neurologist in the follow up clinic visits.

Clinical notes from follow up visits of all recruited cases to the clinic were reviewed and their neurodevelopment status was recorded.
The impact of treatment delay on the neurodevelopment was not assessed in this study.

2.10. Statistics

Data was compiled and collated on Microsoft Excel spreadsheets. Central tendency (mean/median), standard deviation, Mann-Whitney-U test, \( \chi^2 \) and Fisher’s exact test were applied on data using SPSS Software. P values < 0.05 were considered significant.

2.11. Ethics

The study was approved by the local institutional ethics committee (IEC/2018/14). Informed consent was taken from families wherever genetic testing was performed.

3. Results

From a screened total of 124 patients, 113 were eligible; in 11, adequate information was not available from the case records, hence excluded from the study. Mean (±SD) IS onset age was 6.86 months (±4.25). Male to female ratio was 3.3:1.

Brain MRI results were available for all but 5 patients. All 5 had a history of documented birth asphyxia with low APGAR scores and a neonatal clinical course consistent with hypoxic ischemic encephalopathy and later static encephalopathy. Brain MRIs were abnormal in 82 (76%) of the remaining 108 patients. Metabolic screen was normal in all patients, wherever it was performed.

There were 36 patients with a presumed genetic etiology, including 5 patients with clinical features of TS (Fig. 1). One patient who satisfied clinical criteria for a diagnosis of TS did not receive genetic testing due to family reluctance. In the remaining patients, a genetic etiology could be identified in 46% (16/35) patients (Fig. 2). This included 12/31 (39%) of non-TS patients (9/29 on trio WES; 3/22 on array aCGH) and 4 with TS.

The 113 patients after clinical, radiological and genetic evaluation could be subdivided into 3 etiological groups- structural 85; genetic 11; and unknown 17 (Fig. 2). No patient could be classified into infectious, immunologic or metabolic groups.

Etiology was confirmed in 94/113 (83%) patients (Fig. 2). This included 83/85 in the structural group (structural-acquired 77; structural-genetic 6), and 11 in genetic group. Cause could not be determined in 2 patients within the structural-unknown and 17 in unknown group.

3.1. Structural group

From a total of 85 patients, 77 had structural-acquired, 6 structural-genetic, and 2 had structural-unknown etiology (Fig. 2e).

3.1.1. Structural acquired

The structural-acquired group (77/113, 69%) was the largest etiological subgroup. The most common cause in this group was NHBI followed by neonatal asphyxiations brain injury.

Neonatal hypoglycemic brain injury (40/113, 35.3%) was the most common acquired cause of IS in the whole cohort. Low blood sugar levels (mean blood sugar level- 21.4 mg% ±3.83 [±SD]) in the postnatal period were documented in 30/40 patients. In the remaining 10/40, a diagnosis was made based on postnatal history of decreased feeding, lethargy and neuroimaging demonstrating NHBI specific changes.

Nearly all of NHBI patients were male (38/40, 95%) and the majority (29/40, 72%) were born at term. All except two patients (38/40, 95%) had global developmental delay. A significant number also had cortical visual impairment (16/29, 55%) and one had social-communication disorder.

MRIs were accessible and found to be abnormal in all NHBI patients. The majority (36/40, 90%) had bilateral occipital involvement (Fig. 3A) including 11 with associated parietal lobe pathology. Five also had periventricular leukomalacia. Four patients, all with documented postnatal hypoglycemia, had unilateral changes –2 hemispheric atrophy; 1 each had unilateral occipital and parieto-occipital gliosis.

Neonatal asphyxiation brain injury was seen in a total of 29/113 (25.7%) patients (Fig 2); 21/29 (72%) were males. All patients (29/29; 100%) had global developmental delay and static encephalopathy. A significant number also had cortical visual impairment (16/29, 55%) and one had social-communication disorder.

MRIs performed in 24/29 patients, were abnormal in all. The majority showed predominant cortical involvement (Fig. 3B) in
the form of diffuse bilateral or frontal encephalomalacia (12/24), parasagittal (5/24) or peri rolandic gliosis (3/24), while some also had associated basal ganglia (5/24) and/or thalamic (3/24) involvement.

The remaining 8/113 (7%) in the structural-acquired group included 4 with meningitis sequelae (2 tubercular meningitis; 2 neonatal meningitis), 3 perinatal stroke and 1 late hemorrhagic disease of newborn.

### 3.1.2. Structural genetic

There were 6 patients in the structural-genetic group (TS 5; lissencephaly 1). Mutations in the TSC2 gene were detected in 4 of the 5 children diagnosed with TS (one family refused genetic testing; Supplementary data 1-Table S1). Trio exome analysis detected a de novo mutation (Arg309His) in the DYN1C1HI gene (Table 1, case 7) in the child with lissencephaly.

Four of the five TS patients had global developmental delay. Two of them also had social communication disorder.

#### 3.1.3. Structural unknown

There were 2 patients with antenatal cortical malformation (lissencephaly 1; bilateral open lip schizencephaly 1). On further analysis no significant variants were detected on WES and array aCGH; both patients had global developmental delay. The child with schizencephaly also had social communication disorder.

### 3.2. Genetic group

Eleven patients (M: F ratio 1.1:1) had a mutation identified on genetic evaluation (Table 1). All of them had a normal metabolic work up. Neuroimaging (MRI) was available for all and was abnormal in two (cerebellar atrophy 1; corpus callosum dysgenesis 1).
| S. No. | Gender/IS Onset age (Months) | Seizure types (as appeared) | Development | Neuroimaging | Gene | Variant Details | Amino acid change | Zygosity and Segregation/inheritance | Significance ACMG 2015 | Literature |
|--------|-----------------------------|-----------------------------|-------------|--------------|--------------------------------|-------------------|-------------------|-------------------------------------|-----------------------|------------|
| 1°     | F/9                         | Erratic Myoclonus, IS       | GDD, Social communication disorder | Cerebellar atrophy | SCN2A | NM_001040142.1 c.638 T > G | p.Val213Gly* | Heterozygous De novo | Likely Pathogenic | This study PMID: 23935176 [Different variant affecting the same codon V213D] |
| 2°     | M/6                         | Focal Clonic, IS            | GDD, Social communication disorder | Normal | STXBP1 | NM_003165.3 c.1610 T > C | p.Leu537Pro* | Heterozygous De novo | Likely Pathogenic | This study |
| 3°     | M/8                         | Myoclonus, IS, Tonic, IS   | GDD | Normal | GRIN1 | NM_001185090.1 c.2039G > A | p.Arg680GIn* | Heterozygous De novo | Likely Pathogenic | This study |
| 4°     | M/8                         | Myoclonus, IS, Tonic, IS   | GDD | Normal | SIRT3 | NM_001145358.1 c.1888del | p.Ala630SerfsTer55* | Heterozygous De novo | Likely Pathogenic | This study |
| 5°     | M/6                         | IS                          | GDD, Social communication disorder | Normal | CYFIP2 | NM_001037332.2 c.299C > T | p.Arg87Cys* | Heterozygous De novo | Likely Pathogenic | PMID:29534297 |
| 6°     | F/6                         | Tonic Seizures, IS, Focal | GDD | Normal | DYN1H1 | NM_001376.4 c.926G > A | p.Arg309His* | Heterozygous De novo | Likely Pathogenic | Clinvar:RCV000191045.1 |
| 7°     | F/5                         | IS, Focal Clonic, IS        | GDD | Normal | TUBB2A | NM_0001069.2 c.48C > T | p.Arg162Cys* | Heterozygous De novo | Likely Pathogenic | This study |
| 8°     | M/10                        | IS, Focal Clonic            | GDD | Normal | PRUNE | NM_00222.1.1 c.46C > T | p.Arg16Ter | Compound heterozygous variants | Likely Pathogenic | Asp106Asn: PMID:26539891 |
| 9°     | F/10                        | IS, Tonic                   | GDD | Normal | NA | 2q22.1q22.3 (139,135,404–144,963,991)x1 | NA | Likely De novo | Likely Pathogenic | Arg16Ter: This study |
| 10°    | F/5                         | IS, Tonic                   | GDD, Social communication disorder, dyskinesia | Normal | NA | ar1|GRCH37| 5q14.3 (87489736_8844231)x1 | NA | Likely De novo | Likely Pathogenic | Heterozygous deletion involving chromosome 2 (5.8 Mb) indicating monosomy for this region. The genes in this region include SPOPL, NXPH2, YY1P2, LRPIB, KYNU, AMHCAP15 and GTDC1 |
| 11°    | M/5                         | IS, Tonic                   | GDD | Normal | NA | ar1|GRCH37| 5q14.3 (87489736_8844231)x1 | NA | Likely De novo | Pathogenic | Heterozygous deletion of 1.4 Mb on chromosome 5 at q14.3 region, indicating monosomy for this region. This region contains the 3 OMIM genes; LINC00461 (616611), MIR8-2 (611187), MEZ1C |
| 12°    | F/5                         | IS, Tonic                   | GDD, Social communication disorder | Normal | NA | ar1|GRCH37| Xp22.11p11.23 (23309293_47698937)x1 | NA | Likely De novo | Likely Pathogenic | Mosaic loss (76%) on chromosome X within cytoregion p22.11p11.23 (24.3 Mb), indicating mosaic monosomy for this region. This mosaic region contains 76 OMIM genes and overlaps chromosome Xp21 microdeletion syndrome. |

**Abbreviations:** a – Trio exome analysis results; b – Microarray results; IS – Infantile spasms; GDD – Global developmental delay; * – Heterozygous De Novo variant; ** – Compound heterozygous variants (Arg16Ter inherited from mother; Asp106Asn inherited from father); $-parental testing not available. PMID- PubMed reference number. The Annotations are based on (Grch37/h g19). The nucleotide numbering reflects cDNA numbering; the initiation codon is codon 1.
Three patients (2 were dysmorphic) had microdeletions on array aCGH. Eight had point mutations on trio WES in CYFIP2, GRIN1, PRUNE, SCN2A, SIN3A, STXBP1 (two patients), TUBB2A genes (all except one were de novo).

All eleven patients had global developmental delay and a majority (8/11, 73%) also had social-communication disorder.

### 3.3. Unknown group

In 17/113 (15%) patients no etiology could be established, despite extensive radiological, metabolic and genetic evaluation. All had a normal brain MRI.

In this group a smaller proportion of patients had developmental delay (5/17, 29.4%) and social-communication disorder (5/17, 29.4%) as compared to the genetic group.

### 3.4. Lead time to treatment

The median age at which a child was seen by a pediatric neurologist was 8 months (Range 2–72 months). The median lead time to specific spasm treatment for IS was 60 days (0–66 Months). There was a statistically significant difference (p value- 0.00193) in median lead time to treatment between responders (median- 30 days [Range- 0 days to 43 months]) and non-responders (median-90 days [Range- 14 days to 66 months]). The distribution of lead time among responders and non-responders is depicted in supplementary figure (Fig. S1).

### 3.5. Treatment response

All 113 patients initially received treatment for IS. The follow up period ranged between 1–26 months (Median – 14 months). Two patients were lost to follow-up, and 1 not treated according to UKISS protocol, so these 3 were excluded from the final analysis of 110 patients. First line treatment was oral steroids in the 105 patients without TS, and vigabatrin in the 5 with TS. All 5 patients with TS had a complete response to vigabatrin.

Overall, 61/110 patients (56%) responded to first-line therapy (Table 2). A further 18 patients (17%) responded to second-line therapy, leaving 31/110 (28%) patients with drug-resistant spasms. There was no difference in age at presentation between those with resistant spasms and those responding to first or second-line therapy. Patients in the structural group were less likely to have resistant spasms than those in the genetic or unknown groups (p = 0.013 (OR 0.30 [0.12–0.76]). We investigated for whether underlying specific etiology was associated with treatment response. In the genetic group more than half (55%) (Table 2) had drug resistant spasms.

There was a linear relationship between lead time to treatment and the presence of resistant spasms at 3 months ($\chi^2$ for trend = 10.0, p = 0.0015) (Table 3).

### 4. Discussion

This study is a comprehensive etiological evaluation of IS patients from a tertiary care hospital in North India. Our hospital serves as both a secondary and tertiary care center for the local population, and for patients from neighboring states. We believe our data authentically reflects the current circumstances of clinicians dealing with IS in India.

In each case the perinatal history was reviewed and confirmed by the same experienced pediatric neurologist. Two radiologists independently reviewed neuroimaging. A comprehensive genetic evaluation was performed, where the perinatal history and investigations were unable to reveal the cause (Fig. 1). Hence we were able to establish etiology in the majority (83%) of our patients. There have been few similar studies with a detailed clinical and genetic evaluation, with an etiological yield of 61–64% [2,3]. These studies though were done in better equipped health care setups, than ours [2,3]. While we had a higher proportion of patients with identified acquired causes compared to prenatal causes, the opposite was true in previous studies [2,3]. All our patients with a presumed genetic cause also had a more comprehensive genetic evaluation which included trio WES and array aCGH. Both these factors could have contributed to the better yield in our study.

In our study, as reported by other authors from India [4–6], the most common acquired cause of IS was due to a perinatal insult. In previous works from India, neonatal asphyxiation brain injury was the commonest antecedent cause [4–6]. In contrast, NHBI was the most common cause of IS in our cohort, representing more than a third of all patients.

The babies with NHBI usually become unwell in first 72 hours of life [26]. These babies can be mistaken for having perinatal asphyxia, since both conditions may present similarly, and blood sugars are often not documented or given due importance [9]. This could be one of the reasons for only a few patients with neonatal hypoglycemia who subsequently developed IS, having been reported in the past [4–6,11]. The reliability of neuroimaging in diagnosing etiologies of epilepsy syndromes is well established, and can be used to circumvent this problem of limited record keeping in resource constrained settings.

### Table 2

| Age at presentation with spasms | N (%) responding to first line therapy | Cumulative N (%) responding to second line therapy | N (%) with resistant spasms at 3 months | P value, Fishers Exact test. (Odds ratio [95% CI]) for resistant spasms at 3 months |
|--------------------------------|--------------------------------------|--------------------------------------------------|----------------------------------------|--------------------------------------------------------------------------------|
| All patients$^*$               | 61/110 (56%)                         | 79/110 (72%)                                     | 31/110 (28%)                           | NA                                                                            |
| Age at presentation with spasms$^{**}$ |                                     |                                                  |                                       |                                                                                |
| ≤ 6 months                     | 40/70 (57%)                          | 53/70 (76%)                                      | 17/70 (24%)                            | > 0.05                                                                       |
| > 6 months                     | 19/36 (53%)                          | 24/36 (66%)                                      | 12/36 (37%)                            |                                                                                |
| Etiological Groups             |                                      |                                                  |                                       |                                                                                |
| Structural                     | 48/82 (59%)                          | 64/82 (79%)                                      | 18/82 (21%)                            | 0.013 (OR 0.30 [0.12–0.76])                                                   |
| Genetic                        | 5/11 (45%)                           | 5/11 (45%)                                       | 6/11 (55%)                             | > 0.05                                                                       |
| Unknown                        | 8/17 (47%)                           | 10/17 (59%)                                      | 7/17 (41%)                             | > 0.05                                                                       |
| Main Etiologies                |                                      |                                                  |                                       |                                                                                |
| NHBI                           | 24/38 (60%)                          | 29/38 (73%)                                      | 8/38 (24%)                             | > 0.05                                                                       |
| Neonatal asphyxia              | 11/27 (38%)                          | 19/27 (62%)                                      | 10/28 (35%)                            | > 0.05                                                                       |
| Tuberous Sclerosis             | 5/5 (100%)                           | 5/5 (100%)                                       | 0/5 (0%)                               | > 0.05                                                                       |
| Other single gene disorder or microdeletion | 5/11 (45%) | 5/11 (45%)                                       | 6/11 (55%)                             | 0.044 (OR 3.70 [1.03–13.21])                                                   |
| Unknown                        | 8/17 (47%)                           | 10/17 (59%)                                      | 7/17 (41%)                             | > 0.05                                                                       |

NHBI= Neonatal Hypoglycemic brain injury; NA= not applicable.

$^*$3/113 patients excluded; $^{**}$Information not available in 7/113 patients.
limited settings [20,22]. NHBI most commonly results in occipital gliosis, in contrast to perinatal asphyxia which causes more periventricular white matter injury [9,20,22,23]. If blood sugar levels were not available, neuroimaging was used as an important objective parameter in determining the most likely etiology, in our study. Udani et al. [9] had also used MRI brain as an objective marker for identifying etiologies in their patients with symptomatic infantile spasms.

The higher incidence of neonatal hypoglycemia in developing countries is due to emphasis on exclusive breast feeding, and lack of support for mothers to help establish lactation [10,26]. These babies are at significant risk to develop hypoglycemia even without any associated risk factors [23]. This is reflected in majority of our NHBI babies being term babies with normal birth weight; this observation was also made in a recent study from India on spectrum of epilepsies associated with NHBI [10].

There appeared to be a significant gender bias (87 males; 77% of total patients) in our study. A similar overwhelming bias has also been noted in previous studies on IS from India, as a male child is usually brought to medical attention earlier in Indian culture [4–6,10].

Using advanced genetic testing (Fig. 1) we could achieve a molecular diagnosis in nearly half (45.7%; 16/35) of patients tested. This included 31% (9/29) yield of trio WES in our study as a first line genetic investigation in non-TS and non-dysmorphic IS patients, results comparable to other similar studies [3,7,27].

Despite the high number tested only 3/22 (13.6%) had significant copy number variants on chromosomal array aCGH, of whom 2 were also dysmorphic. In a similar study of 44 patients with unexplained IS, array aCGH revealed a de novo variant in only 3/44 (7%) of patients [7]. Contrary to what has been suggested [3], we would recommend applying chromosomal microarray first only to patients who along with epilepsy and developmental disability are also dysmorphic, though cost differences between array aCGH and WES must be considered.

In spite of exhaustive genetic investigations, we were still not able to determine an etiology in 19 patients (17 unknown & 2 structural-unknown; Fig. 2). It is possible that including mitochondrial gene sequencing in standard genetic testing protocol [28] and identification of novel genes could potentially unravel the etiology in some of them. Similarly, better neuroimaging techniques in the future might be able to identify small dysplastic lesions in some of the remaining patients [29].

Our study revealed a significant lead time to seeing a pediatric neurologist and initiating appropriate treatment, a delay contributing to resistant spasms later. A significant lead time from spasm onset to first presentation to a pediatric neurologist is not unusual in both a resource limited setting and even in a better equipped health care set up [4,5,15]. The baby is often misdiagnosed to have infantile colic or an excessive startle response at first [15,30]. In developing countries, even after an epilepsy diagnosis, these patients are often managed with inappropriate antiseizure medications [4]. Access to good quality standard neurodiagnostic and neurophysiological testing is also limited and concentrated to single centers, as was also common in our region [31]. All these factors could contribute to the significant delay in diagnosis and appropriate early treatment of infantile spasms.

5. Conclusions

This study highlights the contribution of preventable perinatal insults, particularly neonatal hypoglycemia as an important cause of IS in a resource limited setting. There is an urgent need to develop guidelines for early recognition and optimal management of neonates at risk of developing hypoglycemia. We could also confirm that there was a significant delay in diagnosing and appropriately treating IS patients, leading to increased risk of drug resistant spasms. Hence it is vital for pediatricians, family practitioners, and the general public to be educated about early identification and appropriate treatment of neonates with IS.

| Lead time | N (%) responding to first line therapy | Cumulative N (%) responding to second line therapy | N (%) with resistant spasms at 3 months | χ² test for trend (resistant spasms at 3 months) | N with missing information of treatment response |
|-----------|---------------------------------------|-----------------------------------------------|----------------------------------------|-----------------------------------------------|-----------------------------------------------|
| ≤7 days   | 10/11 (91%)                           | 11/11 (100%)                                  | 0/11 (0%)                              | (χ² = 10.0 (1 d.f.), p = 0.0015)               | 1                                             |
| 8-14 days | 9/16 (56%)                            | 15/16 (94%)                                   | 1/16 (6%)                              |                                               | 0                                             |
| 15 days to 2 months | 30/44 (68%) | 44/44 (92%)                                 | 14/44 (32%)                            |                                               | 2                                             |
| > 2 months | 19/38 (50%)                          | 23/38 (61%)                                  | 15/38 (39%)                            |                                               | 0                                             |
Ethical statement

Funding: None
Consent: The study was approved by the local institutional ethics committee (IEC/2018/14). Informed consent was taken from families wherever genetic testing was performed.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.ebr.2020.100397.

References

[1] West WJ. On a peculiar form of infantile convulsions. The Lancet 1841;35 (911):724-5. https://doi.org/10.1016/S0140-6736(00)41084-4.
[2] Osborne JP, Lux AL, Edwards SW. The underlying etiology of infantile spasms (West syndrome): Information from the United Kingdom Infantile Spasms Study (UKISS) on contemporary causes and their classification. Epilepsia 2010;51:2168-74.
[3] W berries EC, Shellhaas RA, Joshu C, Keator C, Kumar S, Mitchel WG. How should children with West syndrome be efficiently and accurately investigated? Results from the National Infantile Spasms Consortium. Epilepsia 2015;56 (4):617-25. https://doi.org/10.1111/epi.12951.
[4] Kaushik JS, Patra B, Sharma S, Yadav D, Aneja S. Clinical spectrum and treatment outcome of West Syndrome in children from Northern India. Seizure 2013;22(8):617-21. https://doi.org/10.1016/j.seizure.2013.04.014.
[5] Gulati S, Jain P, Kannan L, Sehgal R, Chakraborty B. The clinical characteristics and treatment response in children with west syndrome in a developing country: a retrospective case record analysis. J Child Neurol 2015;30 (11):1440-7. https://doi.org/10.1177/0883073815593094.
[6] Gupta J, Sharma S, Mukherjee SB, Jain P, Aneja S. Neuro-developmental and epilepsy outcomes of children with west syndrome: A cross sectional study from North India. Ann Indian Acad Neurol 2020;23:177-81.
[7] Michaud JL, Lachance M, Hamdan FF, Carman L, Lortie A, Diadoi P, Philippe M, et al. The genetic landscape of infantile spasms. Human Molecular Genetics 2014;23:4846-58.
[8] Wang Y, Du X, Bin R, Yu S, Xia Z, Zheng G, et al. Genetic variants identified from epilepsy of unknown etiology in Chinese children by targeted exome sequencing. Sci Rep 2017;7:40319.
[9] Iidai V, Munof P, Ursekar M, Gupta S. Neonatal hypoglycemic brain-injury, a common cause of infantile onset remote symptomatic epilepsy. Indian Pediatr 2009;46:127-32.
[10] Kapoor D, Sidhathar, Sharma S, Patra B, Mukherjee SB, Penndhe HK. Electroclonic spectrum of childhood epilepsy secondary to neonatal hypoglycemic brain injury in a low resource setting: a 10-year experience. Seizure 2020;79:90-4. https://doi.org/10.1016/j.seizure.2020.05.010.
[11] Yang G, Zou LP, Wang J, Shi X, Tian S, Yang X, et al. Neonatal hypoglycemic brain injury is a cause of infantile spasms. Exp Ther Med 2016;11:2066-70.
[12] Mitra N, Menon RN, McTague A, Radhakrishnan A, Sundaram S, Cherian A, et al. Genotype-phenotype correlates of infantile onset Developmental & epileptic encephalopathy syndromes in South India: a single centre experience. Epilepsy Res 2020;166:10398.
[13] O’Callaghan FJ, Lux AL, Darke K, Edwards SW, Hancock E, Johnson AL, et al. The effect of lead time to treatment and age of onset on development outcome at 4 years in infantile spasms: evidence from the United Kingdom Infantile Spasms Study. Epilepsia 2011;52:1359-64.
[14] Riikonen RS. Favourable prognostic factors with infantile spasms. Eur J Paediatr Neurol 2010;14(1):11-8. https://doi.org/10.1016/j.ejpn.2009.03.004.
[15] Hussain SA, Lay J, Cheng E, Weng J, Sankar R, Raca BC. Recognition of infantile spasms is often delayed: the ASSIST study. J Pediatrics 2017;190:215-221.e1. https://doi.org/10.1016/j.jpeds.2016.09.005.
[16] Yusukasitis CJ, Buznikov MRZ, Howell I, Allen IE, Kapur K, Dlugos DJ, Scheffer IE, Poduri A, Sherr EH. Infantile spasms of unknown cause: predictors of outcome and genotype-phenotype correlation. Pediatr Neurol 2018:87:48–56. https://doi.org/10.1016/j.pediatrneurol.2018.04.012.
[17] Hrachovey RA, Frost Jr JD, Kellaway P. Hypsarrythmia: variations on the theme. Epilepsia 1984;25:317–25.
[18] Richard S, Aziz N, Bale S, Dick D, Das S, Gaster-Foster J, et al. Standards and Guidelines for the interpretation of sequence variants: a joint consensus recommendation of American College of Medical Genetics and Genomics and the association of Molecular Pathology. Genet Med 2015;17:405–24.
[19] Volpe JJ. Neonatal encephalopathy: an inadequate term for hypoxic-ischemic encephalopathy. Ann Neurol 2012;72(2):156–66. https://doi.org/10.1002/ana.22547.
[20] Gururaj A, Sztriha L, Dawodu A, Nath KR, Varady E, Nork M, et al. CT and MRI patterns of hypoxic-ischemic brain damage following perinatal asphyxia. J Trop Pediatr 2002;48:5-8.
[21] Lucas A, Morley R, Cole TJ. Adverse neurodevelopmental outcome of moderate neonatal hypoglycemia. BMJ 1988;297:1304–8.
[22] Barkowich AJ, Ali FA, Rowley HA, Bass N. Imaging patterns of neonatal hypoglycemia. Am J Neuroradiol 1998;19:523-8.
[23] Gu MM, Amda F, Yuan TM. Brain injury in neonatal hypoglycemia: a hospital-based cohort study. Clinic Med Insights: Pediatr 2019;13:1-6.
[24] Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhot L, Hirsch E, Jain S, Mathern GW, Mosli SH, Nordli DR, Perucca E, Tomson T, Wiebe S, Zhang Y-H, Zuberi SM. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsy 2017;58(4):512–21. https://doi.org/10.1111/epilo.12709.
[25] Lux AL, Edwards SW, Hancock E, Johnson AL, Kennedy CR, Newton RW, et al. The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial. Lancet 2004;364:1773-4.
[26] J Ahmad H, Chisti AL, Neonatal hypoglycemia, an underreported entity in high risk neonates. Pak Pediatr J 2020; 24:9-11.
[27] Dimassi S, Labalme A, Ville D, Calamis J, Courny E, Dureuil C, et al. Neuronal hypoglycemia, an underreported entity in high risk neonates. Pediatrie 2017; 48:3-9.
[28] Chugani HT, Shields WD, Shewmon DA, Olson DM, Phelps ME, Peacock WJ. Infantile spasms: 1. PET identifies focal cortical dysgenesis in cryptogenic epilepsy outcomes of children with west syndrome: A cross sectional study. Ann Neurol 1990;27:406-13.
[29] Bearden D. Pediatric neurology in resource-limited settings: a systematic review. Curr Pediatr Rev 2018;6(1):1-6.
[30] Paediatric Neurol 2008;14(1):1-6. https://doi.org/10.1016/j.ped.2017.12.004.
[31] O’Callaghan FJ, Edwards SW, Alber FD, Hancock E, Johnson AL, Kennedy CR, et al. Safety and effectiveness of hormonal treatment versus hormonal treatment with vigabatrin for infantile spasms (ICISS): a randomized, open-label trial. Lancet Neurol 2007;6:715-25. https://doi.org/10.1016/S1474-4422(07)70586-3.
[32] Krumina N, Trop Pediatr 2002;48:5-8.
[33] Hussain SA, Lay J, Cheng E, Weng J, Sankar R, Raca BC. Recognition of infantile spasms is often delayed: the ASSIST study. J Pediatrics 2017;190:215-221.e1. https://doi.org/10.1016/j.jpeds.2016.09.005.
[34] O’Callaghan FJ, Edwards SW, Alber FD, Bora J, Johnson AL, et al. Vigabatrin with hormonal treatment versus hormonal treatment alone (ICISS) for infantile spasms: 18-month outcomes of an open-label, randomized controlled trial. Lancet Child Adolesc Health 2018;2:715-25. https://doi.org/10.1016/S2364-7247(18)30088-8.
[35] Lux AL, Osborne JP. A proposal for case definitions and outcome measures in studies of infantile spasms and west syndrome: consensus statement of the West Delphi Group. Epilepsia 2004;45(11):1416–28. https://doi.org/10.1111/j.1365-2878.2004.09245.x.